statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Latest Ratings for OPRX
 DateFirmActionFromTo Feb 2022Lake StreetMaintainsBuy Nov 2021RBC CapitalMaintainsOutperform Apr 2021RBC CapitalInitiates Coverage OnOutperform
 View More Analyst Ratings...

Expert Ratings For OptimizeRx

OptimizeRx (NASDAQ:OPRX - Get Free Report)s stock had its "outperform" rating restated by stock analysts at Royal Bank of Canada in a report released on Monday, Benzinga reports. They...

Royal Bank of Canada Reiterates "Outperform" Rating for OptimizeRx (NASDAQ:OPRX)

This is a signal that OPRX's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

OptimizeRx (OPRX, $11.42) RSI Indicator left the oversold zone on April 01, 2024

In a report released today, David Grossman from Stifel Nicolaus maintained a Buy rating on OptimizeRx (OPRX Research Report), with a price target...

Stifel Nicolaus Sticks to Their Buy Rating for OptimizeRx (OPRX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on OptimizeRx (OPRX Research Report), Walgreens Boots Alliance (WB...

Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), Walgreens Boots Alliance (WBA) and Kodiak Sciences (KOD)

RBC Capital analyst Sean Dodge maintained a Buy rating on OptimizeRx (OPRX Research Report) on March 28 and set a price target of $17.00. The com...

RBC Capital Keeps Their Buy Rating on OptimizeRx (OPRX)

Q4 2023 OPTIMIZERx Corp Earnings Call Transcript

OPRX's total volume now sits at 392.9K. The +0.00% price change was insignificant, leaving IBM's price at $12.15...

The volume for OptimizeRx stock increased for one day, resulting in a record-breaking daily growth of 228% of the 65-Day Volume Moving Average

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
OPRX stock results show that OptimizeRx beat on revenue for the fourth quarter of 2023.
The post OPRX Stock Earnings: OptimizeRx Beats...

OPRX Stock Earnings: OptimizeRx Beats Revenue for Q4 2023

OptimizeRx Q4 revenue $28.4M

OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell in 2006 and is headquartered in Waltham, MA.

Watchers	812
52-Wk Low	$6.92
52-Wk High	$16.65

Volume	701.00
52-Wk High	$16.65
52-Wk Low	$6.92

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.07	--	--	N/A
Q1'24	-$0.13	-$0.11	13.79%	BEAT
Q4'23	$0.26	$0.26	0.19%	BEAT
Q3'23	$0.03	$0.09	260.00%	BEAT
Q2'23	-$0.02	-$0.01	53.33%	BEAT

OPRX OptimizeRx Corp

About

Feed

News

Sentiment

Earnings

Fundamentals